STOCK TITAN
  1. Home
  2. Sec-filings
  3. NBIX
  4. [Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity

Neurocrine (NBIX) director sells 1,250 shares under Rule 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk sold 1,250 shares of common stock in an open-market transaction on June 4, 2026 at a weighted average price of about $168.06 per share. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on September 15, 2025, and Norwalk now directly holds 2,838 shares.

Positive

  • None.

Negative

  • None.

Insights

Routine planned sale of 1,250 NBIX shares under a 10b5-1 plan.

Director Leslie V. Norwalk completed an open-market sale of 1,250 shares of NEUROCRINE BIOSCIENCES INC common stock at a weighted average price near $168.06 on June 4, 2026. This transaction used a broker and followed Rule 10b5-1 instructions.

The filing notes the trading plan was adopted and effective on September 15, 2025, and company policy restricts changes after adoption. Such pre-planned trades are generally viewed as routine portfolio management, with reduced informational value about the insider’s short-term view, especially as Norwalk retains 2,838 shares.

Insider Norwalk Leslie V
Role Director
Sold 1,250 shs ($210K)
Type Security Shares Price Value
Sale Common Stock 1,250 $168.0573 $210K
Holdings After Transaction: Common Stock — 2,838 shares (Direct)
Footnotes (2)
  1. F1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  2. F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.00 to $168.2550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares sold 1,250 shares Open-market sale on June 4, 2026
Weighted average sale price $168.0573 per share Common stock sale on June 4, 2026
Shares held after transaction 2,838 shares Direct ownership after June 4, 2026 sale
Sale price range $168.00–$168.2550 per share Multiple transactions composing 1,250-share sale
Net shares sold 1,250 shares Net-sell direction per transaction summary
Rule 10b5-1 trading plan regulatory
"The disposition ... was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average sales price per share financial
"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.00 to $168.2550."
beneficial ownership financial
"information regarding the number of shares sold at each price within the range."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did NBIX director Leslie V. Norwalk report?
Leslie V. Norwalk reported selling 1,250 shares of Neurocrine Biosciences common stock. The open-market sale occurred on June 4, 2026, at a weighted average price of about $168.06 per share, leaving her with 2,838 directly held shares after the transaction.

At what price were the 1,250 NBIX shares sold by the director?
The 1,250 Neurocrine Biosciences shares were sold at a weighted average price of approximately $168.06 each. Individual trades occurred between $168.00 and $168.2550 per share, with the broker executing multiple transactions within this disclosed price range.

Was the NBIX insider sale made under a Rule 10b5-1 trading plan?
Yes. The sale was carried out by a broker under a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Company policy also restricts the reporting person from amending or modifying the plan after it is adopted.

How many NBIX shares does Leslie V. Norwalk hold after the sale?
Following the reported sale, Leslie V. Norwalk directly holds 2,838 shares of Neurocrine Biosciences common stock. This figure reflects her position after the 1,250-share open-market disposition executed on June 4, 2026, under the Rule 10b5-1 trading plan.

What does the price range disclosure mean for the NBIX insider sale?
The filing states the 1,250 shares were sold at prices between $168.00 and $168.2550, with a weighted average of about $168.06. The director offers to provide detailed share counts at each price to the issuer, security holders, or SEC staff upon request.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Norwalk Leslie V
(Last)(First)(Middle)
6027 EDGEWOOD BEND CT.
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026S(1)1,250D$168.0573(2)2,838D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.00 to $168.2550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Remarks:
/s/ Darin Lippoldt, Attorney-in-Fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR